Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.32+0.57 (+5.85%)
At close: 04:00PM EDT
10.36 +0.04 (+0.39%)
After hours: 06:51PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    Barrington
    Some in the scientific community is already saying that a 27% cognitive reduction in alzheimer's patients is not significant. But the Alzheimer's Association is quite excited. They said that 27% reduction in cognitive decline may not seem a lot but it gives alzheimer's sufferers an extra 6 months to function and pay their bills. By the way, that's a quote. So just imagine if AVXL slows the cognitive decline by 50% or stops the decline or even improve cognition. It will take off like a rocket. The FDA will almost certainly grant accelerated approval. The Alzheimer's Association will be beating down the FDA door to approve AVXL. With a ph2b/3, it will be approve in Europe.
    The BIIB data reaction shows how desperate a viable treatment is needed for this destructive disease.
  • K
    Koch
    MASSIVE order are coming in at the close, huge volume. Large institutions on the move again🤑🚀
    Bullish
  • D
    Doc
    No matter what people write about, their opinions about the science and the management, their long and short interests, whether they are negative or positive on the company, this pharmaceutical boils down to one question. Does 50mg of anavex 2-73 prove superior to placebo in wild type sigma 1 receptor Alzheimer’s patients? Like Metallica puts it, Nothing Else Matters.
  • N
    New  System
    Anyone has an idea when what month the results will be in the news
    The CEO said in the fall
  • K
    KO
    Alz staying in the news, getting eyeballs now. Folks doing DD are looking at small bios to find the ones with real potential for huge gains. If enough investors start small positions, the SP could take off. AVXL risk/reward is awsome, possibly the best.
    Bullish
  • b
    buster
    Once our products are in the market place we should be trading in the 28-58 range...
  • z
    z
    One of the more interesting questions is if Anavex achieves 50% reduction (high dose) in progression with p value of 0.005, what will the market cap be?
  • K
    KO
    Quite a few AVXL and SAVA investors battening down the hatches right now for hurricane Ian. Still waiting to know where landfall will be. I'm boarded up, 100 yards from mandatory evacuation zone. Prayers go out to all of you also in harms way.

    God Bless and Good Luck
    Bullish
  • d
    dc
    Who is selling under the bid in 1,5 and 10 shares
  • K
    Ken
    I don't believe any Pharma or, bio-tech company can achieve "the Holy Grail" of regeneration of diseased cells back to normal cells ... homeostasis ... that Anavex's 2 - 73 is capable of for early AD patients. It will be deemed "a true wonder drug." I read that somewhere that some, who do not have AD disease want to be able to obtain the drug in the hope that by taking the Anavex drug 2 - 73 that it will prevent their ever getting AD disease o,r even senility.
  • H
    Howard
    Sava down 4 bucks, thoughts?...
    Bullish
  • m
    moon
    Definitely a good news for AD from biogen today. Entire market were down play the Alzheimer’s development over the years. I mean nobody have any confidence that drug companies will be successful in their development ever since the biogen’s previous controversial drug and Sava’s saga. Now we know there is hope and also there maybe a hope from Avxl based on the historical data. It is good that maybe market is finally waking for AD
  • d
    dc
    Ok. So another hospital visit for injection drug looks ok but has side effects

    I'd rather take a pill with no side effects
  • I
    Ivan
    Biogen up $100 a share on news.

    The two pharma companies said their drug lecanemab reduced cognitive and functional decline by 27% relative to a placebo. The findings come over an 18 month stretch in a Phase 3 study of 1,800 patients with early-stage Alzheimers.

    Shares of Biogen surged nearly 50% in pre-market trading Wednesday on the development. The company's ticker page was the most active on Yahoo Finance ahead of the opening bell.
  • b
    buster
    up to 10.40 early pre-market...
  • s
    simon
    Went in at the bottom Friday mid 9s lots of updates around the corner.
    Bullish
  • M
    Michael
    BIogens surge of more than $75 per share is validation AVXL can do the same if not better when it’s AD trial results are published. Stay long!!!
  • J
    Jack
  • S
    Sand Pebble
    I wasn't paying too much attention today but the last I checked, mid afternoon, we were under 600k shares traded. Must of been real busy before end of day? Good volume today.
    Bullish
  • g
    georgejjl
    I was correct again!!! There were over 1 million shares of AVXL bought TODAY in anticipation of NEWS NEXT WEEK!!!

    Good luck and GOD bless,
Advertisement
Advertisement